

●► **Genentech**

*(FDA, Approval)*

FDA approves Genentech's TECENTRIQ and TECENTRIQ HYBREZA as an adjuvant for treating muscle-invasive bladder cancer with ctDNA MRD post cystectomy

●► **BeOne**

*(FDA, Approval)*

FDA provides approval to BeOne's BEQALZI, a BCL2 inhibitor to treat relapsed or refractory mantle cell lymphoma

●► **Taiho Pharma**

*(FDA, Approval)*

Taiho Pharma obtains FDA approval for its INQOVI plus venetoclax as a treatment for newly diagnosed AML in those who are 75 years and older or who are ineligible for intensive induction chemotherapy

●► **Bio-Thera**

*(FDA, Approval)*

Bio-Thera secures approval from FDA for its AVZIVI injection, a tumor-inhibiting humanized monoclonal antibody



► **Partner Therapeutics**

*(FDA, Approval)*

Partner Therapeutics' targeted therapy BIZENGRI gets FDA approval to treat NRG1+ cholangiocarcinoma with disease progression on or after prior systemic therapy

► **Sandoz**

*(EU, Approval)*

Sandoz gains EC approval for its BYSUMLOG and DAZPARDA biosimilar insulin prefilled pens, improving affordability and expanding access to insulin treatment options for diabetes

► **INmune Bio**

*(FDA, Fast Track)*

INmune Bio's pegipanermin receives FDA Fast Track designation, a selective soluble TNF inhibitor for the treatment of early Alzheimer's disease

► **Coya Therapeutics**

*(FDA, Fast Track)*

Coya Therapeutics obtains Fast Track designation from FDA for its COYA 302, a biologic combination therapy with a dual mechanism of action to treat amyotrophic lateral sclerosis



●▶ **Sironax**

*(FDA, Fast Track)*

FDA grants Fast Track designation to Sironax's SIR2501, a SARM1 inhibitor for chemotherapy-induced peripheral neuropathy

●▶ **Servier**

*(FDA, Breakthrough Therapy)*

Servier secures Breakthrough Therapy designation from FDA for its ADC, Emi-Le, directed against B7-H4 in certain cancers including, adenoid cystic carcinoma

●▶ **Collegium Pharmaceutical**

*(Acquisition)*

Collegium Pharmaceutical acquires AZSTARYS, a CNS stimulant to treat ADHD, from Corium Therapeutics for approximately \$650 million

●▶ **Bristol Myers Squibb**

*(Collaboration)*

Bristol Myers Squibb enters into collaboration and license agreements with Hengrui Pharma to accelerate and develop 13 early-stage programs in oncology, hematology and immunology



●► **Fosun Pharma**

*( Collaboration )*

Fosun Pharma and AriBio sign an exclusive global agreement for the development, registration, manufacturing and commercialization of AR1001, a phosphodiesterase-5 inhibitor with disease-modifying potential to treat AD

●► **Alkermes**

*( Phase 3, Results )*

Phase 3 REVITALYZ study of Alkermes evaluating LUMRYZ extended-release oral suspension in adults with idiopathic hypersomnia demonstrates significant improvements in excessive daytime sleepiness compared to placebo

●► **AstraZeneca**

*( Phase 3, Results )*

AstraZeneca's VOLGA Phase 3 trial evaluating IMFINZI in combination with neoadjuvant enfortumab vedotin demonstrates clinically meaningful improvements in EFS and OS in muscle-invasive bladder cancer

●► **AstraZeneca**

*( Phase 3, Results )*

The CALYPSO Phase 3 trial from AstraZeneca assessing AZP-3601 demonstrates clinically meaningful normalization of sCa levels and independence from active vitamin D and oral calcium supplements in adults with chronic HypoPT at week 24

